Ixabepilone and the narrow path to developing new cytotoxic drugs

Journal of Clinical Oncology

Volumn 25, Issue 23, 2007, Pages 3389-3391

  Gianni, Luca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPOTHILONE B; EPOTHILONE D; IXABEPILONE; PACLITAXEL; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; ZK EPOTHILONE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG BINDING; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PRIORITY JOURNAL; SENSORY NEUROPATHY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DRUG DESIGN; EPOTHILONES; FEMALE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; TUBULIN;

EID: 34548169077     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.9504     Document Type: Editorial

References (18)

1. Denduluri N, Low JA, Lee JJ, et al: Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25:3421-3427, 2007
2. Roché H, Yelle L, Cognetti F, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25:3415-3420, 2007
3. Thomas E, Tabernero J, Fornier M, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406, 2007
4. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414, 2007
5. Vansteenkiste JF, Lara PN Jr, Le Chevalier T, et al: Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25:3448-3455, 2007
6. He L, Orr GA, Horwitz SBL Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today 15:1153-1164, 2001
7. Larkin JM, Kaye SB: Epothilones in the treatment of cancer. Expert Opin Investig Drugs 15:691-702, 2006
8. Lee FY, Borzilleri R, Fairchild CR, et al: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437, 2001
9. Lee JJ, Low JA, Croarkin E, et al: Changes in neurological function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 24:2084-2091, 2006
10. Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005
11. Schmidt C: Adaptive design may hasten clinical trials. J Natl Cancer Inst 99:108-109, 2007
12. Rogatko A, Babb JS, Tighiouart M, et al: New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clin Cancer Res 11:5342-5346, 2005
13. Rubin EH, Rothermel J, Tesfaye F, et al: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23:9120-9129, 2005
14. Roché H, Perez EA, Llombart-Cussac A, et al: Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): Data from neoadjuvant and metastatic breast cancer (MBC) trials. Ann Oncol 17:S9, 2006 (abstr 256P)
15. Pusztai L, Gianni L: Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nat Clin Pract Oncol 1:44-50, 2004
16. Baselga J, Gianni L, Llombart A, et al: Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Proceedings of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 305)
17. Pusztai L: Chips to bedside: Incorporation of microarray data into clinical practice. Clin Cancer Res 12:7209-7214, 2006
18. Hess KR, Anderson K, Symmans WF, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244, 2006